BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bridoux A, Moutereau S, Covali-Noroc A, Margarit L, Palfi S, Nguyen JP, Lefaucheur JP, Césaro P, d'Ortho MP, Drouot X. Ventricular orexin-A (hypocretin-1) levels correlate with rapid-eye-movement sleep without atonia in Parkinson's disease. Nat Sci Sleep 2013;5:87-91. [PMID: 23847436 DOI: 10.2147/NSS.S41245] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Stanojlovic M, Pallais JP, Lee MK, Kotz CM. Pharmacological and chemogenetic orexin/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson's disease. Mol Brain 2019;12:87. [PMID: 31666100 DOI: 10.1186/s13041-019-0514-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
2 Trotti LM, Bliwise DL, Keating GL, Rye DB, Hu WT. Cerebrospinal Fluid Hypocretin and Nightmares in Dementia Syndromes. Dement Geriatr Cogn Dis Extra 2021;11:19-25. [PMID: 33790936 DOI: 10.1159/000509585] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Stanojlovic M, Pallais JP, Kotz CM. Chemogenetic Modulation of Orexin Neurons Reverses Changes in Anxiety and Locomotor Activity in the A53T Mouse Model of Parkinson's Disease. Front Neurosci 2019;13:702. [PMID: 31417337 DOI: 10.3389/fnins.2019.00702] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
4 Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Agúndez JA. Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease. Front Cell Neurosci 2014;8:369. [PMID: 25426023 DOI: 10.3389/fncel.2014.00369] [Cited by in Crossref: 13] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
5 Tabikh M, Chahla C, Okdeh N, Kovacic H, Sabatier J, Fajloun Z. Parkinson disease: protective role and function of neuropeptides. Peptides 2021. [DOI: 10.1016/j.peptides.2021.170713] [Reference Citation Analysis]
6 Antelmi E, Pizza F, Donadio V, Filardi M, Sosero YL, Incensi A, Vandi S, Moresco M, Ferri R, Marelli S, Ferini-Strambi L, Liguori R, Plazzi G. Biomarkers for REM sleep behavior disorder in idiopathic and narcoleptic patients. Ann Clin Transl Neurol 2019;6:1872-6. [PMID: 31386270 DOI: 10.1002/acn3.50833] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
7 Yuan Y, Zhang Y, Cheng Y, Hou Y, Huang Z, Ma J, Li N, Zhan S. Cerebrospinal Fluid TNF-α and Orexin in Patients With Parkinson's Disease and Rapid Eye Movement Sleep Behavior Disorder. Front Neurol 2022;13:826013. [DOI: 10.3389/fneur.2022.826013] [Reference Citation Analysis]
8 Kumar S, Behl T, Sehgal A, Singh S, Sharma N, Bhatia S, Al-Harassi A, Abdel-Daim MM, Bungau S. Exploring the Role of Orexinergic Neurons in Parkinson's Disease. Neurotox Res 2021. [PMID: 34495449 DOI: 10.1007/s12640-021-00411-4] [Reference Citation Analysis]
9 Stanojlovic M, Pallais JP, Kotz CM. Inhibition of Orexin/Hypocretin Neurons Ameliorates Elevated Physical Activity and Energy Expenditure in the A53T Mouse Model of Parkinson's Disease. Int J Mol Sci 2021;22:E795. [PMID: 33466831 DOI: 10.3390/ijms22020795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Stanojlovic M, Pallais Yllescas JP Jr, Vijayakumar A, Kotz C. Early Sociability and Social Memory Impairment in the A53T Mouse Model of Parkinson's Disease Are Ameliorated by Chemogenetic Modulation of Orexin Neuron Activity. Mol Neurobiol 2019;56:8435-50. [PMID: 31250383 DOI: 10.1007/s12035-019-01682-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]